San Raffaele Foundation
Executive Summary
Pioneering Italian tech transfer.
You may also be interested in...
BioXell: A New Beginning for Italian Biotech
The creation of Roche spin-off BioXell may signal a change in Italy's hitherto unfriendly biotech environment. Yet much remains to be done.
CTG Pharma SRL
CTG Pharma SRL's founders believe that the unique properties of hydrogen sulfide (H2S) hold the key to exciting new anti-inflammatory therapeutics. The Italian start-up plans to tag already-approved compounds with an H2S-releasing molecule. The strategy has several potential advantages: it would create novel chemical entities, it would reduce the risks of drug development, and it could be applied with a variety of drugs.
GeneMedix's Big Biogeneric Gamble
Patent expiries in Europe on proteins such as EPO and interferon alpha may open up a huge market for cheaper versions of these proteins-one which GeneMedix and others are preparing to tap into. But it's a risky game, since there's still no regulatory process in Europe for approving such products.